Meridian Bioscience Stock

Meridian Bioscience EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Meridian Bioscience (VIVO) as of Sep 11, 2026 is 17.47. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 22.51 — a change of -22.41% (lower).

EV/OCF

17.47

YoY

-22.41%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Meridian Bioscience is 2026 17.47 . EV/OCF (Enterprise Value to Operating Cash Flow) of Meridian Bioscience was 2025 22.51 . It decreases by -22.41% lower compared to the previous year.

The Meridian Bioscience EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2015
33.75 USD
Jan 1, 2016
40.47 USD
Jan 1, 2017
36.08 USD
Jan 1, 2018
42.71 USD
Jan 1, 2019
41.69 USD
Jan 1, 2020
31.48 USD
Jan 1, 2021
22.51 USD
Jan 1, 2022
17.47 USD
The Meridian Bioscience EV/OCF history
YEAREV/OCFYoY
17.47-22.41%
22.51-28.48%
31.48-24.50%
41.69-2.38%
42.71+18.35%
36.08-10.83%
40.47+19.89%
33.75-11.06%
37.95
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Meridian Bioscience is 17.47 in 2026.

EV/OCF (Enterprise Value to Operating Cash Flow) of Meridian Bioscience changed from 22.51 to 17.47, representing a -22.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Meridian Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Meridian Bioscience

All Key Metrics — Meridian Bioscience